Hypertrophic Cardiomyopathy Clinical Trial
A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy
The purpose of this study is to evaluate the mavacamten impact on myocardial structure with cardiac magnetic resonance imaging (CMR) in adult participants with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) [New York Heart Association (NYHA) Functional Class II or III].
Diagnosed with obstructive hypertrophic cardiomyopathy (oHCM), in accordance with current American College of Cardiology Foundation/American Heart Association and European Society of Cardiology guidelines as below:
Left ventricular outflow tract (LVOT) peak gradient ≥ 30 mm Hg and ≥ 50 mm Hg after Valsalva or after exercise
Left ventricular ejection fraction (LVEF) ≥ 55% at rest
New York Heart Association (NYHA) functional class II or III symptoms
A known infiltrative or storage disorder causing cardiac hypertrophy that mimics oHCM
Documented obstructive coronary artery disease or history of myocardial infarction
A history of resuscitated sudden cardiac arrest or life-threatening ventricular arrhythmia within 6 months prior to screening
An implantable cardioverter defibrillator (ICD) or pacemaker, or another contraindication for cardiac magnetic resonance imaging (CMR)
Note: Other protocol-defined inclusion/exclusion criteria apply
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 16 Locations for this study
Darlinghurst New South Wales, 2010, Australia
Graz , 8036, Austria More Info
Wien , 1090, Austria More Info
Genk Limburg, 3600, Belgium More Info
Roeselare West-Vlaanderen, 8800, Belgium More Info
Calgary Alberta, T2N 1, Canada
Prague Praha, Hlavní Mesto, 140 2, Czechia
Madrid , 28034, Spain More Info
Bern , 3010, Switzerland
Geneva , 1205, Switzerland More Info
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.